Krasnodembskaya’s research group works with Mesenchymal Stem Cells (MSC) and MSC derived extracellular vesicles (EVs) with the  particular focus  on the MSC based   cell therapy for acute and chronic lung diseases.  Our central goal is to understand how MSC (and their EVs) work in the context of the injury microenvironment, how MSC modulate reparative capacities of the host cells and if we can enhance MSC therapeutic potential. We hope that this research will allow to develop better cell therapies as well as to  identify new therapeutic targets. The current research projects are investigating effects of MSC EVs on pulmonary macrophage polarisation and MSC EV modulation of distal lung endothelial and epithelial cell functions. Given difficulties in  appling  the knowledge gained in animal models in a logical way to the human disease process, we have strong interest in physiologically relevant models of the human lung tissue such as organoids, lung-on-chip and decel-recel approach.  In our work we actively use a novel organoid model of the distal lung based on primary human cells (established by us) and a model of ex vivo cultured lung slices.